



ANDA 71-602

Food and Drug Administration
Rockville MD 20857

Vitarine Pharmaceuticals, Inc.
Attention: Gail P. Prince
227-15 N. Conduit Avenue
Springfield Gardens, New York 11413

OCT 5 1987

Dear Madam:

Reference is made to your abbreviated new drug application dated October 23, 1986, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Desipramine Hydrochloride Tablets, USP, 75 mg.

We acknowledge receipt of your communications of March 3 and September 21, 1987 enclosing final printed labeling.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved.

Any significant change in the conditions outlined in this abbreviated application requires an approved supplemental application before the change may be made, except for changes made in conformance with other provisions of Section 314.70 of the New Drug Regulations.

Postmarketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80 and 314.81 of the Regulations.

This Administration should be advised of any change in the marketing status of this drug.

For Initial Campaigns: We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your immediate advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Advertising and Labeling (HFN-240). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

For Subsequent Campaigns: We call your attention to Section 314.81(b)(3) of the Regulations which requires that materials for any subsequent advertising or promotional campaign, at the time of their initial use, be submitted to our Division of Drug Advertising and Labeling (HFN-240) with a completed Form FD-2253.

Sincerely yours,

Marvin Seife, M.D.

Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics